CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine

References

• Tabe Y, Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr Hematol Malig Rep. 2015;10:96–103.
   PubMed Web of Science ®Google Scholar
• Felipe Rico J, Hassane DC, Guzman ML. Acute myelogenous leukemia stem cells: from bench to bedside. Cancer Lett. 2013;338:4–9.
   PubMed Web of Science ®Google Scholar
• Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2:17ra9.
   PubMed Web of Science ®Google Scholar
• Terwijn M, Feller N, van Rhenen A, et al. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur J Cancer. 2009;45:1692–1699.
   PubMed Web of Science ®Google Scholar
• Gonen M, Sun Z, Figueroa ME, et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012;120:2297–2306.
   PubMed Web of Science ®Google Scholar
• Cerny J, Yu H, Ramanathan M, et al. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br J Haematol. 2013;160:262–266.
   PubMed Web of Science ®Google Scholar
• Nakase K, Kita K, Kyo T, et al. Prognostic relevance of cytokine receptor expression in acute myeloid leukemia: interleukin-2 receptor alpha-chain (CD25) expression predicts a poor prognosis. PLoS ONE. 2015;10:e0128998.
   PubMed Web of Science ®Google Scholar
• Ikegawa S, Doki N, Kurosawa S, et al. CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission. Leuk Lymph. 2016;57:1375–1381.
   PubMed Web of Science ®Google Scholar
• Miltiades P, Lamprianidou E, Vassilakopoulos TP, et al. Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine. Blood Cancer J. 2014;4:e187.
   PubMed Web of Science ®Google Scholar
• Tawfik B, Pardee TS, Isom S, et al. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol. 2016;7:24–31.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. JCO. 2012;30:2670–2677.
   PubMed Web of Science ®Google Scholar
• Ritchie EK, Feldman EJ, Christos PJ, et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leuk Lymph. 2013;54:2003–2007.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107:7473–7478.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Cancer IAfRo, Organization WH. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.
   Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. JCO. 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv Preprint arXiv; 2013. p. 3.
   Google Scholar
• Lai Z, Markovets A, Ahdesmaki M, et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 2016;44:e108.
   PubMed Web of Science ®Google Scholar
• De Baets G, Van Durme J, Reumers J, et al. SNPeffect 4.0: on-line prediction of molecular and structural effects of protein-coding variants. Nucleic Acids Res. 2012;40:D935–D939.
   PubMed Web of Science ®Google Scholar
• Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023–2036.
   PubMed Web of Science ®Google Scholar
• Zorn E, Nelson EA, Mohseni M, et al. IL-2 regulates FOXP3 expression in human CD4 + CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108:1571–1579.
   PubMed Web of Science ®Google Scholar
• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665–674.
   PubMed Web of Science ®Google Scholar
• Frank DA, Robertson MJ, Bonni A, et al. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci USA. 1995;92:7779–7783.
   PubMed Web of Science ®Google Scholar
• Padros MR, Salamone MC, Zunszain PA, et al. Differential expression of CD25 and HC2 antigens on subtypes of acute myeloid leukemias. Eur J Haematol. 1989;42:436–440.
   PubMed Web of Science ®Google Scholar
• Kobayashi CI, Takubo K, Kobayashi H, et al. The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells. Blood. 2014;123:2540–2549.
   PubMed Web of Science ®Google Scholar
• Lecine P, Algarte M, Rameil P, et al. Elf-1 and Stat5 bind to a critical element in a new enhancer of the human interleukin-2 receptor alpha gene. Mol Cell Biol. 1996;16:6829–6840.
   PubMed Web of Science ®Google Scholar
• Guo Z, Wang A, Zhang W, et al. PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. Blood. 2014;124:1777–1789.
   PubMed Web of Science ®Google Scholar
• Garg S, Shanmukhaiah C, Marathe S, et al. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/beta catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia. Eur J Haematol. 2015;96:309–317.
   PubMed Web of Science ®Google Scholar
• Angelini DF, Ottone T, Guerrera G, et al. A leukemia-associated CD34/CD123/CD25/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res. 2015;21:3977–3985.
   PubMed Web of Science ®Google Scholar
• Schneider F, Hoster E, Schneider S, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol. 2012;91:9–18.
   PubMed Web of Science ®Google Scholar
• Fujiwara SI, Muroi K, Yamamoto C, et al. CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. Hematology. 2017;22:347–353.
   PubMed Web of Science ®Google Scholar